Recombinant epidermal growth factor - Bharat Biotech

Drug Profile

Recombinant epidermal growth factor - Bharat Biotech

Alternative Names: hrecEGF - Bharat Biotech; Recombinant human epidermal growth factor - Bharat Biotech; REGEN-D 150; REGEN-D 60; REGEN-D® 10; rhEGF - Bharat Biotech; rhuEGF - Bharat Biotech

Latest Information Update: 27 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bharat Biotech
  • Class Antiulcers; Growth factors
  • Mechanism of Action Epidermal growth factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Burns; Diabetic foot ulcer; Wounds

Most Recent Events

  • 21 Mar 2017 Bharat Biotech plans a phase II trial for Foot disorders (Cracked feet) in India (CTRI/2017/03/008000)
  • 06 Mar 2017 Bharat Biotech initiates enrolment in a phase II trial for Foot disorders (Cracked feet) in India (Topical) (CTRI/2017/03/008000)
  • 15 Jul 2005 Launched for Burns (first- and second-degree burns) in India (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top